Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.47 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.47 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811768 | 0.87 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1MAPTHSPB1 | |
| SCHEMBL15858815 | 0.83 | TSHR (0.56) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL30062398 | 0.83 | HSPB1 (0.56) | KMT2AALDH1A1MEN1MAPTHSPB1 | |
| SCHEMBL397137 | 0.83 | HSPB1 (0.56) | KMT2AALDH1A1MEN1MAPTHSPB1 | |
| SCHEMBL14477748 | 0.83 | HSD17B10 (0.56) | KMT2AALDH1A1MEN1MAPTTDP1 | |
| SCHEMBL16878869 | 0.82 | HSPB1 (0.51) | KMT2AALDH1A1MEN1MAPTHSPB1 | |
| SCHEMBL1135919 | 0.81 | HSPB1 (0.50) | ALDH1A1HSPB1TDP1 | |
| SCHEMBL20328418 | 0.80 | TDP1 (0.66) | KMT2AALDH1A1MEN1MAPTHSPB1 | |
| SCHEMBL397931 | 0.80 | TDP1 (0.66) | KMT2AALDH1A1MEN1MAPTHSPB1 | |
| SCHEMBL20328412 | 0.80 | TDP1 (0.66) | KMT2AALDH1A1MEN1MAPTHSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-20190262426-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA A/S (DK) | 2019-08-29 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160089446-A1 | Modified Hydrogels | ASCENDIS PHARMA A/S (DK) | 2016-03-31 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | ASCENDIS PHARMA INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150258205-A1 | Hydrogel Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | Ascendis Phama A/S (DK) | 2014-10-30 | — | — | US | disclosed |
| EP-1097918-A1 | PROCESS FOR PRODUCING 4-SUBSTITUTED-2-NITRO-FLUOROBENZENES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089446-A1 | Modified Hydrogels | CD44, DNPH1, PHYKPL | KMT2A 3268/4885ALDH1A1 229/4885MEN1 4613/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | KMT2A 4600/4885ALDH1A1 239/4885MEN1 3163/4885 |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | KMT2A 3995/4885ALDH1A1 712/4885MEN1 1619/4885 |
| US-20160296600-A1 | Relaxin Prodrugs | RXFP1, RXFP2, RXFP3 | KMT2A 3675/4885ALDH1A1 3629/4885MEN1 202/4885 |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | KMT2A 1454/4885ALDH1A1 725/4885MEN1 1880/4885 |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | KMT2A 2943/4885ALDH1A1 4667/4885MEN1 1182/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | KMT2A 3627/4885ALDH1A1 631/4885MEN1 1495/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | KMT2A 3217/4885ALDH1A1 219/4885MEN1 3272/4885 |
| US-20150258205-A1 | Hydrogel Prodrugs | CD44, DNPH1, PHYKPL | KMT2A 3156/4885ALDH1A1 282/4885MEN1 3605/4885 |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | SLC6A7, PRAP1, PELP1 | KMT2A 4580/4885ALDH1A1 3956/4885MEN1 3669/4885 |
| US-20190262426-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1R1, IL1B | KMT2A 2894/4885ALDH1A1 87/4885MEN1 3789/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | KMT2A 2556/4885ALDH1A1 193/4885MEN1 3497/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | KMT2A 2556/4885ALDH1A1 193/4885MEN1 3497/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | KMT2A 4600/4885ALDH1A1 239/4885MEN1 3163/4885 |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | VEGFA, KDR, FLT1 | KMT2A 4574/4885ALDH1A1 805/4885MEN1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.